Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-AlbuminuricDiabetic Kidney Disease.

A panel of cytokines and growth factors, mediating low-grade inflammation and fibrosis, was assessed in patients with type 2 diabetes (T2D) and different patterns of chronic kidney disease (CKD). Patients with long-term T2D (N = 130) were classified into four groups: no signs of CKD; estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m without albuminuria; albuminuria and eGFR ≥60 mL/min/1.

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in Mice, a Model of Type 2 Diabetes.

Recent data have indicated the emerging role of glomerular autophagy in diabetic kidney disease. We aimed to assess the effect of the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and their combination, on glomerular autophagy in a model of type 2 diabetes. Eight-week-old male mice were randomly assigned to treatment with empagliflozin, linagliptin, empagliflozin-linagliptin or vehicle for 8 weeks.

Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes.

Background: Wnt1-inducible signaling pathway protein 1, or cellular communication network factor 4 (CCN4), a member of CCN family of secreted, extracellular matrix associated signaling proteins, recently was validated as a novel adipose tissue derived cytokine.

Objective: To assess the relationships between circulating CCN4, adipose tissue distribution and function, and chronic low-grade inflammation in subjects with type 2 diabetes.

Methods: We observed 156 patients with type 2 diabetes and 24 healthy controls.

Linagliptin alleviates fatty liver disease in diabetic / mice.

Aim: To study the effects of linagliptin on the structural signs of non-alcoholic fatty liver disease (NAFLD) in / mice.

Methods: Male diabetic / mice (BKS.Cg-Dock7/Lepr/J) aged 10 wk received the dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin (10 mg/kg) or saline as a placebo once per day by gavage for 8 wk.

Association of IL2, TNFA, IL4 and IL10 Promoter Gene Polymorphisms with the Rate of Progression of the HIV Infection.

The rate of transition from one stage to another during the course of HIV infection is characterized by changes in the cytokine network balance. The alterations in the cytokine network balance during HIV infection depend on the individual profile of cytokine production predetermined by the functioning of the genes encoding the immunomodulators. The purpose of this research is to study the distribution in the frequency of allelic variants of the promoter regions of the genes encoding pro-inflammatory (T-330G IL2 and G-308A TNFA) and anti-inflammatory (C-590T IL4 and C-597A IL10) cytokines among healthy individuals of European origin and in HIV-infected patients with various rates of HIV progression (fast and slow).

Polymorphism of Immune Response Genes as a Factor for Predisposition to Development of Diseases.

The association of particular allelic variants of genes coding proteins, such as transporter associated with processing (TAP) and heat shock protein (HSP), involved in endocellular processing of endogenous antigens, with synovium pathology accompanied with urogenital infection was observed. The particular alleles of TAP1 and TAP2 genes appeared to be the factor of predisposition or resistance for Chlamidia trachomatis but not for Mycoplasma hominis. At the same time, the relative risk for C.